Legend Biotech Corp (LEGN) Current Deferred Revenue (2019 - 2024)
Legend Biotech (LEGN) has disclosed Current Deferred Revenue for 5 consecutive years, with $46.9 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Current Deferred Revenue fell 11.58% year-over-year to $46.9 million, compared with a TTM value of $46.9 million through Dec 2024, down 11.58%, and an annual FY2024 reading of $46.9 million, down 11.58% over the prior year.
- Current Deferred Revenue was $46.9 million for Q4 2024 at Legend Biotech, down from $53.0 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $53.0 million in Q4 2023 and bottomed at -$60.6 million in Q4 2021.
- Average Current Deferred Revenue over 4 years is -$3.9 million, with a median of -$4.1 million recorded in 2020.
- The sharpest move saw Current Deferred Revenue tumbled 218.84% in 2020, then dropped 10.23% in 2021.
- Year by year, Current Deferred Revenue stood at -$55.0 million in 2020, then fell by 10.23% to -$60.6 million in 2021, then surged by 187.41% to $53.0 million in 2023, then decreased by 11.58% to $46.9 million in 2024.
- Business Quant data shows Current Deferred Revenue for LEGN at $46.9 million in Q4 2024, $53.0 million in Q4 2023, and -$60.6 million in Q4 2021.